Japanese startup Craif, focused on early cancer detection, has successfully closed a funding round, highlighting interest in innovative medical technologies.
Technology Used for Early Cancer Detection
Craif is developing an AI-based solution using microRNA (miRNA) biomarkers found in urine. They focus on miRNA instead of traditional cell-free DNA, as miRNA is actively secreted by early cancer cells and could be useful for diagnosis.
- **Biomarker Choice:** miRNA can detect cancer at early stages. - **Sample Type:** urine, simplifying the collection process. - **AI Power:** analyzes miRNA patterns to determine cancer risk.
Craif Funding: Expansion and R&D
Craif has completed its Series C funding round, raising $22 million, increasing total funding to $57 million. This round was led by existing investor X&KSK and attracted new participants, such as Unreasonable Group and others.
CEO Ryuichi Onose stated that the round was completed at a valuation just under $100 million. The funds will focus on entering the U.S. market and enhancing research.
Global Ambitions
Craif is aiming for the U.S. market, opening an office in San Diego and planning trials for their miSignal test. These efforts confirm the company's intention to expand its influence in the world's largest healthcare market. Together with medical institutions in the U.S., the startup is already collecting samples for analysis.
Additionally, Craif is exploring the use of its technology for detecting neurological diseases, indicating broad future potential for its platform.
Craif's successful $22 million funding round underscores the growing interest in innovation for early cancer detection, making diagnostics more accessible and effective.
